Decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome - A pilot study

Archives of Medical Science

Volumn 4, Issue 4, 2008, Pages 417-423

  Barylski, Marcin ^a   Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Pawlicki, Lucjan ^a   Kowalski, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular complications; Chronic kidney disease; Glomerular filtration rate; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PILOT STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60249095827     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sarmiento Méndez LM, Roca-Cusachs Coll A, Arroyo Díaz JA, Benet Gustà MT, Solé Villa MJ, Franco Peral M. Comparison of the definitions of the metabolic syndrome according to ATP III and IDF [Spanish]. Rev Clin Esp 2008; 208: 333-8.
2. Tuomilehto J, Lindström J, Eriksson JG Valle TT, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
3. Rysz J, Banach M, Stolarek RA, et al. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 2007; 20: 444-52.
4. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
5. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16: 459-66.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S17-266.
7. Chien KL, Hsu HC, Lee YT, Chen MF. Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis 2008; 197: 860-7.
8. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998; 279: 585-92.
9. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-53.
10. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) Study. J Am Soc Nephrol 2003; 14: 2919-25.
11. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group (EUTox). Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-56.
12. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure. Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9.
13. Komukai K, Ogawa T, Yagi H, et al. Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J 2008; 72: 1152-7.
14. Hillege HL, Nitsch D, Pfeffer MA, et al.; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.
15. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008; 17: 450-6.
16. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-49.
17. Chen J, Muntner P, Hamm LL, et al. Insulin. resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-77.
18. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
19. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-36.
20. Ryu S, Chang Y, Woo HY, et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 2008.
21. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.
22. Rasić-Milutinović Z, Perunicić-Peković G. Clinical importance and pathogenic mechanisms of insulin resistance in chronic renal insufficiency (part I): insulin resistance in patients with chronic renal insufficiency [Croatian]. Med Pregl 2000; 53: 45-50.
23. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42.
24. Iseki K, Ikemiya Y, Fukiyama K. Serum cholesterol and risk of end-stage renal disease in a cohort of mass screening. Clin Exp Nephrol 1998; 2: 18-24.
25. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-91.
26. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-50.
27. Verhave JC, Gansevoort RT, Hillege HL, De Zeeuw D, Curhan GC, De Jong PE. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 2004; 15: 1316-22.
28. Saracino A, Morrone LF, Suriano V, et al. A simple method for correcting overestimated glomerular filtration rate in obese subjects evaluated by the Cockroft and Gault formula: a comparison with 51Cr EDTA clearance. Clin Nephrol 2004; 62: 97-103.
29. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763-73.
30. Verhave JC, Gansevoort RT, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE; PREVEND study group. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 2004; 15: 1316-22.
31. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002; 62: 1743-9.
32. Samuelsson O, Attman PO, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998; 9: 1482-8.
33. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42.
34. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
35. Joles JA, van Goor H, van Der Horst ML, van Tol A, Elema JD, Koomans HA. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. Lab Invest 1995; 73: 912-21.
36. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl 1999; 71: S51-3.
37. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-7.
38. Olbricht CJ, Wanner C, Thiery J, et al. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999; 71: S113-6.
39. Miyata J, Takebayashi S. Effect of hyperlipidemia on glomerular sclerosis in unilateral nephrectomized rats. Acta Pathol Jpn 1987; 37: 1433-9.
40. Keane WF, O'Donnell MP, Kasiske BL, et al. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993; 4: 187-94.
41. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43: 218-25.
42. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52.
43. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B-9B.
44. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: S2-S5.
45. Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. Kidney Int Suppl 1994; 45: S51-3.
46. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 1995; 48: 363-71.
47. Park YS, Guijarro C, Kim Y, et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998; 31: 190-4.
48. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
49. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
50. Rysz J, Błaszczak R, Banach M, et al. Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation. Arch Immunol Ther Exp 2007; 55: 335-40.
51. Barylski M, Kowalczyk E, Banach M, Ciećwierz J, Pawlicki L, Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 2008; 59: (in press).
52. Filippatos TD, Tsimihodimos V, Kostapanos M, et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 2008; 4: 263-9.